

## FORM 7

### **MONTHLY PROGRESS REPORT**

#### **Atlas Global Brands Inc.**

Name of Listed Issuer: **Atlas Global Brands Inc.** (the "Issuer").

Trading Symbol: **ATL**

Number of Outstanding Listed Securities: **151,066,781 Common Shares**

Date: **February 7, 2023**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**Over the previous month, the Issuer's business and operations have been focused on the transition from completion of its previously announced fundamental change transaction to planning and integration activities of the newly combined group of companies.**

**The fundamental change transaction consisted of a reverse take-over transaction ("RTO Transaction"), with each of Atlas Biotechnologies Inc. ("Atlas Biotech"), AgMedica Bioscience Inc. ("AgMedica") and Cambrosia Ltd. ("Cambrosia") and the concurrent acquisition by Cambrosia of each of Tlalim Pappo Ltd., Pharmacy Baron Ltd., and R.J. Regavim Ventures Ltd., privately held operating cannabis pharmacies in Israel (collectively, the "Cambrosia Acquisitions" and together with the acquisition of Silver Phoenix by Atlas Biotech, AgMedica and Cambrosia, the "Transaction").**

**The RTO Transaction was completed pursuant to the terms of conditions of the amalgamation and share exchange agreement dated July 14, 2022, as amended, among Silver Phoenix, Atlas Biotech, AgMedica, Cambrosia, 2432998 Alberta Ltd. ("Subco 1"), 14060407 Canada Inc. ("Subco 2") and the ordinary shareholders of Cambrosia (the "Amalgamation and Share Exchange Agreement").**

**The issuer's shares began trading on January 13, 2023 under the symbol ATL.**

2. Provide a general overview and discussion of the activities of management.

**In the previous month, management's activities have been focused on completing its application for listing on the CSE (including the appointment of IR Labs Inc for provision of Investor Relations services and with Generation IACP Inc. for provision of market maker services), integration activities of the newly combined group of companies and negating the terms of the proposed transactions described as item 12 below)**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Not applicable.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Not Applicable.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**No material new business relationships were established in the period.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Not Applicable**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**As announced on January 12, 2023, the Issuer entered into a letter of intent (a "LOI") with a privately owned Licensed Cannabis Producer (the "Canadian LP") based in Ontario to acquire 100% of the Canadian LP's outstanding shares in exchange for 10,000,000 Issuer common shares at a deemed price of \$1.00 per share. The Canadian LP will add an additional 3,500 KGs of GACP and CUMCS certified production capacity to the Issuer as well as access to hundreds of additional genetics.**

**As also announced on January 12, 2023, the Issuer entered into an LOI to acquire 51% controlling interest in an Israeli licensed distributor ("Trading**

House”) as well as two pharmacies licensed to dispense medical cannabis. The proposed transaction would further expand Issuer’s vertical integration in the Israeli market.

Both above noted agreements are arm’s length transactions and definitive agreements are expected to be signed in Q1 2023.

8. Describe the acquisition of new customers or loss of customers.

**Not Applicable.**

7. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Not Applicable.**

8. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Not Applicable.**

9. Report on any labour disputes and resolutions of those disputes if applicable.

**Not Applicable.**

10. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Not Applicable.**

11. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Not Applicable.**

12. Provide details of any securities issued and options or warrants granted.

**The Issuer granted a total of 4,021,027 stock options exercisable at \$1.00 per share to its directors, officers and consultants. All options shall vest quarterly over the three-year period commencing from the date of grant and are subject to a four-month hold period in compliance with the policies of the CSE.**

13. Provide details of any loans to or by Related Persons.

**Not Applicable.**

14. Provide details of any changes in directors, officers or committee members.

**On January 10, 2023, the Issuer announced the appointment of Peter Van Mol as Interim Chief Financial Officer and Natalie Douglas as Corporate Secretary.**

**Subsequently, on January 31, 2023, following the completion of a transition period, Bernard Yeung was appointed Chief Executive Officer, replacing**

**Interim CEO Sheldon Croome, and Jason Cervi was appointed Chief Financial Officer, replacing Interim CFO Peter Van Mol.**

15. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Form 2A Listing Statement dated December 30, 2022 under the heading "Risk Factors" which is available on the Issuer's SEDAR profile at [www.sedar.com](http://www.sedar.com).**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **February 7, 2023**

**Jason Cervi, CPA**

Name of Director or Senior  
Officer

**"Jason Cervi"**

Signature

**Chief Financial Officer**

Official Capacity

|   |                                 |                           |
|---|---------------------------------|---------------------------|
| <b>Issuer Details</b><br>Name of Issuer | For Month End                   | Date of Report<br>YY/MM/D |
| <b>Atlas Global Brands Inc.</b>         | <b>January 2023</b>             | <b>23/02/07</b>           |
| Issuer Address                          |                                 |                           |
| <b>566 Riverview Drive, Unit 104</b>    |                                 |                           |
| City/Province/Postal Code               | Issuer Fax No.<br>(   )         | Issuer Telephone No.      |
| <b>Chatham, Ontario N7M 0N2</b>         |                                 | <b>(844) 415 – 6961</b>   |
| Contact Name                            | Contact Position                | Contact Telephone No.     |
| <b>Bernard Yeung</b>                    | <b>CEO</b>                      | <b>(844) 415 – 6961</b>   |
| Contact Email Address                   | Web Site Address                |                           |
| <b>invest@atlasglobalbrands.com</b>     | <b>https://atlasgrowers.com</b> |                           |